The latest round of Big Pharma earnings calls delivered a sweeping look at the opportunities and challenges shaping the biopharma industry heading into the second half of 2026.
Quarterly earnings seasons have long served as a window into strategic priorities, and this past quarter was packed with significant developments across multiple fronts.
Among the standout themes was the accelerating rollout of artificial intelligence across pharmaceutical operations, signalling a shift in how major drugmakers approach research and commercialisation.
The oral GLP-1 battle between Novo Nordisk and Eli Lilly continued to dominate conversation, with both companies vying for supremacy in one of the most competitive drug categories in recent memory.
Novo Nordisk’s chief executive expressed confidence in the company’s trajectory, saying he has “no doubt” about an eventual share price recovery as the Wegovy pill “continues to wow” observers and patients alike.
Sanofi and Eli Lilly (NYSE: LLY) were among the companies highlighted in a Q2 scorecard breakdown, alongside Regeneron and Astellas, as biopharma posted a notable sales boom during the quarter.
Sanofi’s new chief executive is reportedly “looking deeply” at the company’s late-stage pipeline as a clinical clearout continues to reshape the French drugmaker’s strategic direction.
Sarepta’s incoming chief executive Michael Severino faces a series of critical milestones that will be closely watched by investors as the company seeks to demonstrate its growth credentials.
Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Biotech Senior Editor James Waldron discussed how several new chief executives are finding their footing inside organisations undergoing significant strategic transition.
The editors also identified which drugs appear poised to cross the one billion dollar sales threshold in 2026, a benchmark that remains a defining measure of commercial success in the pharmaceutical industry.
With new leadership installed at multiple major companies and the GLP-1 market intensifying, the competitive dynamics across biopharma look set to accelerate further through the remainder of the year.